Andrew Scharenberg
Chief Executive Officer presso Umoja Biopharma, Inc.
Profilo
Andrew Scharenberg is the founder of Generation Bio Co. (founded in 2017).
Dr. Scharenberg is also the founder of Umoja Biopharma, Inc. Dr. Scharenberg's current job is as an Executive Partner at MPM BioImpact, Inc. (since 2019).
Dr. Scharenberg's former jobs include being an Advisor at bluebird bio, Inc. (2014-2017), Chief Scientific Officer at Cellectis, Inc. (2011-2014), and Chief Scientific Officer at Casebia Therapeutics LLC (2017-2019).
Dr. Scharenberg graduated from UNC School of Medicine with a graduate degree in 1993.
Posizioni attive di Andrew Scharenberg
| Società | Posizione | Inizio |
|---|---|---|
Umoja Biopharma, Inc.
 Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Chief Executive Officer | - |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/06/2019 |
Precedenti posizioni note di Andrew Scharenberg
| Società | Posizione | Fine |
|---|---|---|
Casebia Therapeutics LLC
 Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC is a joint venture company that focuses on discovering, developing, and commercializing gene-editing therapeutics to treat genetic causes of bleeding disorders and autoimmune diseases. The company is based in Cambridge, MA. | Corporate Officer/Principal | 01/08/2019 |
| BLUEBIRD BIO, INC. | Consultant / Advisor | 01/06/2017 |
Cellectis, Inc.
 Cellectis, Inc. Pharmaceuticals: MajorHealth Technology Part of Cellectis SA, Cellectis, Inc. engages in the upstream research of genome engineering and in the development of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers. The private company is based in New York, NY. André Choulika has been the CEO of the company since 2014. | Corporate Officer/Principal | 30/06/2014 |
| GENERATION BIO CO. | Founder | - |
Formazione di Andrew Scharenberg
| UNC School of Medicine | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| GENERATION BIO CO. | Health Technology |
| Aziende private | 4 |
|---|---|
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Cellectis, Inc.
Cellectis, Inc. Pharmaceuticals: MajorHealth Technology Part of Cellectis SA, Cellectis, Inc. engages in the upstream research of genome engineering and in the development of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers. The private company is based in New York, NY. André Choulika has been the CEO of the company since 2014. | Health Technology |
Casebia Therapeutics LLC
Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC is a joint venture company that focuses on discovering, developing, and commercializing gene-editing therapeutics to treat genetic causes of bleeding disorders and autoimmune diseases. The company is based in Cambridge, MA. | Health Technology |
Umoja Biopharma, Inc.
Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Andrew Scharenberg
